Greenhaven Fund Bets Big on AI for Cellebrite

Greenhaven Road Capital achieved an approximate 11% net return in the second quarter of 2026. The investment firm is implementing strategic portfolio changes, including reducing concentration and increasing investments with imminent catalysts. They will also adopt a proactive approach to taking profits.

The fund's research emphasizes owning strong businesses and challenging consensus views, with several major investments expected to undergo significant events within the year. Despite current market multiple declines, the underlying business growth suggests a positive outlook for returns.

A significant holding highlighted is Cellebrite DI Ltd., an Israeli digital forensics company. Although Cellebrite's stock experienced a notable decline, Greenhaven believes AI will ultimately benefit the company, contrary to market sentiment. Cellebrite recently launched its first AI product, aimed at assisting investigators by leveraging its domain expertise in investigations and evidence handling.